John Valliant, Chief Executive Officer at Fusion Pharmaceuticals Inc. (FUSN), sold 1,289 shares at $6.02 ($8K) on 2022-04-20, disclosed to the SEC on 2022-04-22.
Scheduled sale ($8k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.02 | 367 | $2K | 28.5% |
| 2 | $6.01 | 922 | $6K | 71.5% |
| Total | $6.01 avg | 1,289 | $8K | 100% |
| Filing → |
| FUSN | SELL | 2022-04-08 | $16K | — | Filing → |
| FUSN | SELL | 2022-04-05 | $29K | — | Filing → |
| FUSN | SELL | 2022-04-01 | $2K | — | Filing → |